Do Allergy Shots Help With Asthma? The Disease-Modifier Evidence

Allergy shots do not cure asthma, but they produce disease modification that can substantially reduce its severity and medication requirements. Studies show SCIT reduces asthma symptom scores by SMD -0.59 across 88 randomized trials, cuts inhaled corticosteroid requirements by approximately 40%, and lowers bronchial hyperreactivity to both allergen-specific and non-specific triggers. The most striking outcome is asthma prevention in children: the PAT study found that SCIT in children with allergic rhinitis reduced asthma development with an odds ratio of 2.52 over 10 years — meaning the immune retraining achieved by SCIT can prevent the disease from progressing at all in some patients. These benefits persist 7 or more years after stopping a 3 to 5 year course. No treatment, including SCIT, guarantees complete and permanent elimination of asthma.

SCIT is appropriate for patients with allergic (IgE-mediated) asthma — identified by positive skin prick testing (wheal 3mm or larger) or specific IgE values of 0.35 kUA/L or higher to aeroallergens, combined with symptoms that correlate with allergen exposure. SCIT is NOT appropriate for non-allergic asthma subtypes: exercise-induced bronchoconstriction, aspirin-exacerbated respiratory disease, obesity-related asthma, and occupational irritant asthma are not IgE-mediated and will not respond to immunotherapy. A critical prerequisite is asthma control: AAAAI/ACAAI practice parameters state that SCIT should not be administered when FEV1 is below 70% predicted or when asthma is uncontrolled. Patients must stabilize their asthma on appropriate controller medications before initiating SCIT.

Yes — meta-analysis demonstrates that SCIT reduces inhaled corticosteroid requirements by approximately 40% in allergic asthmatic patients. The Abramson Cochrane review (2010) found medication score SMD of -0.53, representing a meaningful reduction in daily rescue and controller inhaler use. This steroid-sparing effect is clinically significant because long-term high-dose inhaled corticosteroid use carries cumulative side effects including bone density reduction, adrenal suppression, and increased infection susceptibility. For patients who are frustrated by escalating controller therapy and want to address the allergic root cause rather than just managing downstream airway inflammation, SCIT offers a pathway to step down from high-dose inhaler regimens. This transition should be managed carefully with your allergist and pulmonologist.

The PAT study provides the strongest evidence that SCIT can prevent asthma in children with allergic rhinitis. Moller et al. (2002) randomized 205 children to 3 years of SCIT or open control and found significantly fewer asthma diagnoses in the SCIT group during treatment. Niggemann's 5-year follow-up confirmed an odds ratio of 2.68 favoring SCIT for asthma prevention. Jacobsen et al. 10-year follow-up showed the benefit persisted 7 years after stopping SCIT, with 25% asthma incidence in SCIT children versus 45% in controls. Translating to practical numbers: approximately 5 to 6 children must be treated with SCIT to prevent one new asthma case. This disease-modification advantage is greatest in younger children with shorter disease duration — early initiation of SCIT in children with seasonal rhinitis and emerging asthma symptoms appears to offer the most protective benefit.

Allergy shots are safe for patients with well-controlled, mild-to-moderate allergic asthma. The key safety requirement is asthma control at the time of each injection: AAAAI/ACAAI practice parameters specify that SCIT should not be administered when FEV1 is below 70% predicted or when asthma symptoms are uncontrolled. Your allergist should screen for asthma symptoms and, when appropriate, check peak flow before each injection. Patients with severe uncontrolled asthma face a higher risk of anaphylaxis and systemic reactions with SCIT — this is the dominant risk factor in AAAAI surveillance data for fatal SCIT reactions. Once asthma is well-controlled on appropriate medication, SCIT can be safely initiated and has been shown to further improve asthma control over the course of treatment. Carrying a rescue inhaler to injection appointments is standard practice.

Most patients with allergic asthma notice meaningful improvement in asthma symptom frequency and severity within 6 to 12 months of starting SCIT, as the maintenance dose is reached and immune tolerance begins to build. Medication reductions — including inhaled corticosteroid step-down — typically begin occurring in the first year and continue through 2 to 3 years of treatment. The full asthma disease-modification benefit, including durable post-treatment protection, requires at least 3 years of consistent SCIT per the EAACI guidelines. Research by Zheng et al. (2023) in pediatric HDM-SCIT found that FEV1 improvements were documented in the HDM-monosensitized subgroup after 3 years, supporting the importance of completing the full treatment duration rather than stopping early when symptoms improve.

If your asthma is non-allergic, SCIT will not help — and this distinction is critical before investing in a 3 to 5 year treatment course. Non-allergic asthma subtypes include exercise-induced bronchoconstriction (EIB), aspirin-exacerbated respiratory disease (AERD), obesity-related asthma, and occupational asthma from chemical irritants. These subtypes are NOT IgE-mediated and do not respond to allergen-based immunotherapy. Specific IgE testing or skin prick testing with standard aeroallergen panels can confirm whether an allergic component is present. Patients with non-allergic or mixed-phenotype asthma may be better candidates for biologic therapies: omalizumab targets free IgE, dupilumab blocks the IL-4/IL-13 pathway, and mepolizumab targets IL-5-driven eosinophilic inflammation. Your allergist can determine which asthma subtype you have and which treatment pathway is most likely to help.